Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMbrave151: Atezolizumab + Bevacizumab in Advanced Biliary Tract Cancer
NCT04677504Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of bevacizumab in biliary cancer (2 arms), sponsored by Roche. Primary endpoint: Progression Free Survival at 14 months. Started Feb 2021; status: completed.
02
Drugs
bevacizumab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on NCT04677504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677504.